title: Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
abstract: We describe the clinical activity of the ABL kinase inhibitor STI571 in a patient with accelerated phase of chronic myeloid leukemia (CML) relapsing after a second allogeneic BMT and with minimal levels of donor chimerism. STI571 resulted in rapid elimination of leukemic cells with ensuing prolonged severe leukopenia and neutropenia complicated by neutropenic fever and colitis. Subsequent hematopoietic recovery was driven by donor derived cells and was associated with grade 3 graft-versus-host disease (GVHD). STI571 induced sustained hematological and cytogenetic remission combined with controllable GvHD, therapeutic goals not achieved by two preceding allogeneic transplants and repeated donor lymphocyte transfusions (DLT).
authors.affiliation: Medizinische Klinik III, Department of Haematology, Johann Wolfgang-Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Wassmann
authors.forename: S A
authors.initials: SA
authors.lastname: Klein
authors.forename: U
authors.initials: U
authors.lastname: Scheuring
authors.forename: H
authors.initials: H
authors.lastname: Pfeifer
authors.forename: H
authors.initials: H
authors.lastname: Martin
authors.forename: H
authors.initials: H
authors.lastname: Gschaidmeier
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: O G
authors.initials: OG
authors.lastname: Ottmann
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001549:Benzamides; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003092:Colitis / Q000139:chemically induced; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007165:Immunosuppression Therapy; D016898:Interferon-alpha / Q000627:therapeutic use; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000628:therapy; D017710:Lymphocyte Transfusion; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D018365:Neoplasm, Residual; D009503:Neutropenia / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016879:Salvage Therapy; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D001549:Benzamides; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D006918:Hydroxyurea